Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold von Neumann, Peter J, Cohen, Joshua T, Weinstein, Milton C

Volltext

Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018 von Kim, David D., Silver, Madison C., Kunst, Natalia, Cohen, Joshua T., Ollendorf, Daniel A., Neumann, Peter J.

Volltext

An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2] von Garrison, Louis P., Pauly, Mark V., Willke, Richard J., Neumann, Peter J.

Volltext

Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States von Doshi, Jalpa A., Ph.D, Hodgkins, Paul, Ph.D, Kahle, Jennifer, Ph.D, Sikirica, Vanja, Pharm.D, Cangelosi, Michael J., M.P.H, Setyawan, Juliana, Pharm.D, Erder, M. Haim, Ph.D, Neumann, Peter J., Sc.D

Volltext

Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time von Neumann, Peter J., ScD

Volltext

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted von Neumann, Peter J, Thorat, Teja, Zhong, Yue, Anderson, Jordan, Farquhar, Megan, Salem, Mark, Sandberg, Eileen, Saret, Cayla J, Wilkinson, Colby, Cohen, Joshua T

Volltext

Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report von Garrison, Louis P., PhD (cochair), Neumann, Peter J., ScD (cochair), Erickson, Pennifer, PhD, Marshall, Deborah, PhD, Mullins, C. Daniel, PhD

Volltext

A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial von Reindollar, Richard H., M.D, Regan, Meredith M., Sc.D, Neumann, Peter J., Sc.D, Levine, Bat-Sheva, M.D, Thornton, Kim L., M.D, Alper, Michael M., M.D, Goldman, Marlene B., Sc.D

Volltext

Adherence to the iDSI reference case among published cost-per-DALY averted studies von Emerson, Joanna, Panzer, Ari, Cohen, Joshua T, Chalkidou, Kalipso, Teerawattananon, Yot, Sculpher, Mark, Wilkinson, Thomas, Walker, Damian, Neumann, Peter J, Kim, David D

Volltext

Embracing the science of value in health von Krahn, Murray, MD MSc, Bryan, Stirling, PhD, Lee, Karen, MA, Neumann, Peter J., ScD

Volltext

Prevention of non-communicable disease: best buys, wasted buys, and contestable buys von Isaranuwatchai, Wanrudee, Teerawattananon, Yot, Archer, Rachel A, Luz, Alia, Sharma, Manushi, Rattanavipapong, Waranya, Anothaisintawee, Thunyarat, Bacon, Rachel L, Bhatia, Tazeem, Bump, Jesse, Chalkidou, Kalipso, Elshaug, Adam G, Kim, David D, Reddiar, Sumithra Krishnamurthy, Nakamura, Ryota, Neumann, Peter J, Shichijo, Arisa, Smith, Peter C, Culyer, Anthony J

Volltext

The Changing Face of the Cost-Utility Literature, 1990–2012 von Neumann, Peter J., ScD, Thorat, Teja, MSc, MPH, Shi, Jennifer, BS, Saret, Cayla J., BA, Cohen, Joshua T., PhD

Volltext

Cost-effectiveness Thresholds Used by Study Authors, 1990-2021 von Neumann, Peter J, Kim, David D

Volltext

Bias in published cost effectiveness studies: systematic review von Bell, Chaim M, Urbach, David R, Ray, Joel G, Bayoumi, Ahmed, Rosen, Allison B, Greenberg, Dan, Neumann, Peter J

Volltext

QALYs in 2018—Advantages and Concerns von Neumann, Peter J, Cohen, Joshua T

Volltext

Toward Better Data Dashboards for US Drug Value Assessments von Neumann, Peter J.

Volltext

Cost-Effectiveness Analysis 2.0 von Neumann, Peter J, Sanders, Gillian D

Volltext

Measuring the Value of Prescription Drugs von Neumann, Peter J, Cohen, Joshua T

Volltext

An assessment of the methodological quality of published network meta-analyses: a systematic review von Chambers, James D, Naci, Huseyin, Wouters, Olivier J, Pyo, Junhee, Gunjal, Shalak, Kennedy, Ian R, Hoey, Mark G, Winn, Aaron, Neumann, Peter J

Volltext

Does preventive care save money? Health economics and the presidential candidates von Cohen, Joshua T, Neumann, Peter J, Weinstein, Milton C

Volltext